Cargando…

Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda

OBJECTIVES: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by the WHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Eziefula, Alice Chijioke, Staedke, Sarah G, Yeung, Shunmay, Webb, Emily, Kamya, Moses, White, Nicholas J, Bousema, Teun, Drakeley, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612795/
https://www.ncbi.nlm.nih.gov/pubmed/23535703
http://dx.doi.org/10.1136/bmjopen-2013-002759
_version_ 1782264687588540416
author Eziefula, Alice Chijioke
Staedke, Sarah G
Yeung, Shunmay
Webb, Emily
Kamya, Moses
White, Nicholas J
Bousema, Teun
Drakeley, Chris
author_facet Eziefula, Alice Chijioke
Staedke, Sarah G
Yeung, Shunmay
Webb, Emily
Kamya, Moses
White, Nicholas J
Bousema, Teun
Drakeley, Chris
author_sort Eziefula, Alice Chijioke
collection PubMed
description OBJECTIVES: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by the WHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisinin-resistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status. METHODS AND ANALYSIS: In this prospective, four-armed randomised placebo-controlled double-blinded trial, children aged 1–10 years, weighing over 10 kg, with haemoglobin ≥8 g/dl and uncomplicated P falciparum malaria are treated with artemether lumefantrine and randomised to receive a dose of primaquine (0.1, 0.4 or 0.75 mg base/kg) or placebo on the third day of treatment. Participants are followed up for 28 days. Gametocytaemia is measured by quantitative nucleic acid sequence-based analysis on days 0, 2, 3, 7, 10 and 14 with a primary endpoint of the number of days to gametocyte clearance in each treatment arm and secondarily the area under the curve of gametocyte density over time. Analysis is for non-inferiority of efficacy compared to the reference dose, 0.75 mg base/kg. Safety is assessed by pair-wise comparisons of the arithmetic mean (±SD) change in haemoglobin concentration per treatment arm and analysed for superiority to placebo and incidence of adverse events. Ethics and dissemination Approval was obtained from the ethical committees of Makerere University School of Medicine, the Ugandan National Council of Science and Technology and the London School of Hygiene and Tropical Medicine. RESULTS: These will be disseminated to inform malaria elimination policy, through peer-reviewed publication and academic presentations.
format Online
Article
Text
id pubmed-3612795
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36127952013-07-08 Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda Eziefula, Alice Chijioke Staedke, Sarah G Yeung, Shunmay Webb, Emily Kamya, Moses White, Nicholas J Bousema, Teun Drakeley, Chris BMJ Open Infectious Diseases OBJECTIVES: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by the WHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisinin-resistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status. METHODS AND ANALYSIS: In this prospective, four-armed randomised placebo-controlled double-blinded trial, children aged 1–10 years, weighing over 10 kg, with haemoglobin ≥8 g/dl and uncomplicated P falciparum malaria are treated with artemether lumefantrine and randomised to receive a dose of primaquine (0.1, 0.4 or 0.75 mg base/kg) or placebo on the third day of treatment. Participants are followed up for 28 days. Gametocytaemia is measured by quantitative nucleic acid sequence-based analysis on days 0, 2, 3, 7, 10 and 14 with a primary endpoint of the number of days to gametocyte clearance in each treatment arm and secondarily the area under the curve of gametocyte density over time. Analysis is for non-inferiority of efficacy compared to the reference dose, 0.75 mg base/kg. Safety is assessed by pair-wise comparisons of the arithmetic mean (±SD) change in haemoglobin concentration per treatment arm and analysed for superiority to placebo and incidence of adverse events. Ethics and dissemination Approval was obtained from the ethical committees of Makerere University School of Medicine, the Ugandan National Council of Science and Technology and the London School of Hygiene and Tropical Medicine. RESULTS: These will be disseminated to inform malaria elimination policy, through peer-reviewed publication and academic presentations. BMJ Publishing Group 2013-03-26 /pmc/articles/PMC3612795/ /pubmed/23535703 http://dx.doi.org/10.1136/bmjopen-2013-002759 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions this is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Infectious Diseases
Eziefula, Alice Chijioke
Staedke, Sarah G
Yeung, Shunmay
Webb, Emily
Kamya, Moses
White, Nicholas J
Bousema, Teun
Drakeley, Chris
Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title_full Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title_fullStr Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title_full_unstemmed Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title_short Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
title_sort study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in uganda
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612795/
https://www.ncbi.nlm.nih.gov/pubmed/23535703
http://dx.doi.org/10.1136/bmjopen-2013-002759
work_keys_str_mv AT eziefulaalicechijioke studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT staedkesarahg studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT yeungshunmay studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT webbemily studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT kamyamoses studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT whitenicholasj studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT bousemateun studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda
AT drakeleychris studyprotocolforarandomisedcontrolleddoubleblindedtrialofthedosedependentefficacyandsafetyofprimaquineforclearanceofgametocytesinchildrenwithuncomplicatedfalciparummalariainuganda